CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews.com
Research analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, HC Wainwright reduced their price target on CASI Pharmaceuticals from $6.00 to $4.00 and set a […]
Research analysts at StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the biotechnology company’s stock. Separately, HC Wainwright reduced their price target on CASI Pharmaceuticals from $6.00 to $4.00 and set a […]
